Aim Peripheral arterial disease (PAD), a marker of elevated vascular risk, is highly prevalent in general practice. We aimed to investigate patient characteristics and outcomes of PAD patients treated according to the guidelines versus those who were not. Methods The Patient Care Evaluation-Peripheral Arterial Disease Study (PACE-PAD) was a multicenter, cluster randomized, prospective, longitudinal cohort study of patients with PAD in primary care, who were followed up for death or vascular events over 18 months. Guideline orientation was assumed if patients received anticoagulant/antiplatelet therapy, exercise training, and (if applicable) advice for smoking cessation and therapy of diabetes mellitus, hypertension, or hypercholesterolemia, respectively. Results Of the 5,099 PAD patients (mean age 68.0± 9.0 years, 68.5% male subjects) who were followed up, 22.5, 34.6, 30
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Background
Substantial advances have been made in the understanding of peripheral arterial disease (PAD) and its implications (Belch et al. 2003) . A series of studies have shown that PAD is highly prevalent in the primary care setting and the general population. For example, the German Epidemiological Trial on Ankle Brachial Index (getABI) in 6,880 patients aged at least 65 years found PAD in 21.0% of patients [asymptomatic PAD as evidenced by a low anklebrachial index (ABI) <0.9 in 12.3% and symptomatic PAD in 8.7%] ). The German Heinz Nixdorf Recall Study (4,814 unselected patients aged 45-75 years) reported PAD in 8.2% of men and 5.5.% of women (asymptomatic PAD: 6.4% of men and 5.1% of women) (Kroger et al. 2006) .
Further, the increasing awareness of the association of PAD with generalized atherosclerosis in other vascular territories has secured its role in primary and secondary prevention of cardiovascular disease. PAD patients carry a high risk of premature death, and of cardiovascular and cerebrovascular events (Meves et al. 2010 ). According to a recent meta-analysis of Heald et al., this risk is doubled, even if all other conventional cardiovascular risk factors are accounted for (Heald et al. 2006) . This is of particular importance, as PAD signals a risk higher than-for example-smoking or diabetes mellitus and can therefore guide physicians in selecting patients at particularly high risk. Against the background of the high disease burden of PAD associated with increased risk of vascular events, an aggressive approach to treat cardiovascular risk factors is recommended in all major guidelines, e.g., those of the TransAtlantic Inter-Society Consensus (TASC II) (Norgren et al. 2007 ), the American Heart Association (AHA)/ American College of Cardiology (ACC) (Hirsch et al. 2006) , and the newly released joint recommendations of the German Society of Angiology (DGA) and other societies (Deutsche Gesellschaft für Angiologie und Gesellschaft für Gefäßmedizin 2009).
The primary care setting is of particular importance for the management of PAD patients. The family physician needs to be efficient in identifying high-risk patients, as he serves as a gatekeeper for the selection of patients for further assessment or treatment by specialists (Grumbach et al. 1999) and has a pivotal role in the long-term management of patients (Kröger et al. 2010) .
While in other countries the situation of PAD patients in primary care has been repeatedly addressed (Hirsch et al. 2001; Khan et al. 2007) , corresponding data from the German healthcare system are limited. Against this background, the Patient Care Evaluation-Peripheral Arterial Disease (PACE-PAD) Study was initiated. We have previously described the baseline results of the study, with a focus on the current diagnostics and therapy (i.e., management) of patients with newly diagnosed, suspected, or confirmed PAD, with particular focus on the interaction between general physician and specialist care (Neumann et al. 2009 ). In the present article on the 18-month follow-up, we report (1) the differences of patient characteristics and other factors between patients treated according to guidelines and those who were not and (2) the outcomes of guidelineoriented therapy on the incidence of cardiovascular, cerebrovascular, or peripheral vascular events in patients with newly diagnosed PAD.
Methods
Design and study flow PACE-PAD is a multicenter, cluster randomized, observational, non-interventional prospective longitudinal study, which followed patients with confirmed PAD in Fontaine stages I-IV at three visits over 18 months (Fig. 1) . The study was conducted according to the principles of "Good Epidemiological Practice (GEP)" (Arbeitsgruppe Epidemiologische Methoden der Deutschen Arbeitsgemeinschaft Epidemiologie (DAE)). Protection of patient and center data was ensured. According to a statement of the legal department of the University of Duisburg-Essen, for this non-interventional study a formal approval was not necessary.
Study course
Baseline Patients were eligible for inclusion, if they had suspected symptomatic PAD, i.e., newly diagnosed intermittent claudication (IC) or IC-like complaints with PAD suspected by the treating physician. Further, patients with suspected asymptomatic PAD were eligible for inclusion, if they were aged 55 years or above and had (1) previous myocardial infarction and/or (2) previous ischemic stroke and/or (3) manifest type 1 or type 2 diabetes mellitus and/or (4) current smoking (for more than 10 years each). If PAD had been diagnosed prior to baseline, patients were not eligible for further evaluations (exclusion criterion).
Follow-up/longitudinal study If the suspicion of PAD was confirmed at the baseline visit, patients were followed up for 18 months. Three follow-up (F/U) visits (F/U 1 at 6 months, F/U 2 at 12 months, and F/U 3 at 18 months) were scheduled to collect the following information: incidence of cardiovas-cular events (stable or unstable angina pectoris, myocardial infarction, or coronary revascularization with or without stenting), cerebrovascular events [stroke or transient ischemic attacks (TIA), prolonged reversible ischemic neurological deficit (PRIND), revascularization of the carotids], or peripheral revascularization or amputation, respectively.
The longitudinal study endpoints were myocardial infarction, stroke, or minor/major amputation due to PAD. Further, it was assessed whether patients received guideline-oriented management during follow-up, which was assessed using six quality indicators for each patient, using a standardized questionnaire (Table 1 ). The quality indicators were defined and assessed by an interdisciplinary board (composed of clinical experts in the fields of angiography, cardiology, and neurology as well as a methodology specialist regarding evidence-based medicine). They comprised prescription of exercise training in the Fontaine stages I and II, recommendation of smoking cessation, management of arterial hypertension, diabetes 
Statistics
The original sample size was calculated based on the assumption that the cumulative incidence of vascular events after 18 months was 6.8% in PAD patients with guidelineoriented therapy versus 9.8% in PAD patients not receiving such therapy. A sample of 3,483 symptomatic patients (of whom at least 85% were assumed to have diagnosed PAD) and of 20,485 patients with risk factors (of whom at least 10% were assumed to have diagnosed PAD) was required to obtain a power of 80% at a significance level of 5%. It was planned to test primarily the hypothesis that the cumulative incidence of cardiac, cerebrovascular, and peripheral vascular events during the follow-up period would be lower in PAD patients with guideline-oriented management compared to PAD patients without such management. Using cross tables, frequency distributions, and descriptive statistics, the distributions of variables between the two patient strata were compared. In all analyses, a two-sided or the chi-square p value <0.05 (to evaluate differences between proportions for two or more than two groups) was considered to denote statistical significance. All analyses were performed with SPSS Version 15 for Windows (SPSS Inc., Chicago, IL, USA).
Results
Characteristics Patients were included by 2,768 physicians. The flowchart in Fig. 1 displays the disposition of patients in the baseline part of the study and during the three follow-up examinations. Of the 6,129 PAD confirmed patients who were originally included at baseline, 22.5% were in Fontaine stage I, 64.7% in stage II, 7.8% in stage III, and 3.5% in stage IV (1.5% not specified). At F/U 1, 4,645 PAD patients (75.8%), at F/U 2, 4,201 patients (68.5%), and at F/U 3, 3,910 patients (63.8%) were documented. Overall there were 5,099 patients with at least one documented follow-up visit which could be included in the analyses. factors were high (82.0-92.5%). The great majority of the current smokers received the general advice to stop smoking (90.7%). Management of hypertension, diabetes mellitus, hypercholesterolemia, and antiplatelet therapy in line with the respective guidelines was reported in no less than 88% of the PAD patients each (see details in Fig. 3 ).
Characterization Table 2 provides an overview of demographic and clinical patient characteristics in the total PAD follow-up cohort, grouped by guideline orientation status. There were (limited) differences between groups, particularly with regards to mean patient age and diabetes status. The mean patient age was slightly lower in the group treated according to guidelines compared to the group which was not treated in such a way (66.9 vs 68.5 years). Diabetes was more prevalent in the latter group. In contrast, the rate of patients with previous ischemic events (e.g., myocardial infarctions) and atherothrombotic manifestations (e.g., angina pectoris) was substantially higher in the guideline orientation group. An analysis by Fontaine status showed that guideline orientation was higher in the early PAD disease stages: while in stage I 30.3% of patients were treated according to guidelines, in stage III only 9.8% and in stage IV 18.0% were managed accordingly (Table 3) .
Outcomes after 18 months During the 18-month follow-up period in the total PAD cohort, 224 cerebrovascular/coronary deaths, 457 all-cause deaths, 140 ischemic strokes, 116 myocardial infarctions, 100 minor, and 68 major amputations were reported (Fig. 4a) . Figure 4b displays the overall event rates (first event only) at the different followup visits. Overall, there were 973 events reported during the 18-month follow-up period, 468 at F/U 1, 280 at F/U 2, and 225 at F/U 3. Table 4 provides an overview of all vascular event rates grouped by guideline orientation status, and Table 5 of first event only. There was a statistically significant difference between the two subgroups with more overall, cerebrovascular, and peripheral events in the group not treated according to guidelines. However, a lower number of vascular deaths (coronary, cerebrovascular) and all-cause deaths were reported in this group (Table 4) .
With the exception of F/U 3, where in the group not treated according to guidelines more first events occurred, there was no statistically significant difference concerning the first event (Table 5) .
Discussion
While the role of PAD as a marker of high risk for cardiovascular disease has been fostered, data regarding the actual everyday care of patients with PAD are limited. According to the present study, firstly, guideline-oriented therapy which accounts for all major quality indicators is the exception rather than the rule. Secondly, unexpected results were noted in terms of long-term outcomes with no major differentiation between the subgroups which were divided according to orientation vs non-orientation to guidelines.
In recent years, a number of studies have investigated treatment rates and intensity in PAD patients. More than a decade ago, one of the most authoritative studies about the treatment situation of PAD patients, PARTNERS, reported relatively low treatment rates in 1,865 PAD patients (54% on antiplatelets, 56% on lipid-lowering drugs, 88% on antihypertensives, and 85% on antidiabetics). The getABI is an ongoing non-interventional study in 6,880 unselected individuals aged 65 years or older to assess risk factor profile, treatment, and prognosis of PAD patients in primary care. In the patients with PAD alone assessed at the baseline examination in 2001, antiplatelets were prescribed in 53% (versus 65% if coronary or cerebrovascular disease was present), lipid-lowering agents in 40.0%, antihypertensives in 93.3%, and antidiabetics in 74.4% (Pittrow et al. 2003) . Further, in the pooled analysis of three large French observational studies (ECLAT 1, PRISMA, APRES), patients with PAD alone received antiplatelets in 78.9%, lipid-lowering agents in 40.4%, antihypertensives in 25.8%, and antidiabetics in 17.0% (Bongard et al. 2004) . The large contemporary REACH Registry reported in patients with manifest PAD and the respective concomitant disease or condition drug treatment rates of 92% for hypertension, 86% for diabetes, 70% for hyperlipidemia, and 82% for antiplatelet use (Bhatt et al. 2006 ). While at first glance these rates appear satisfactory, in that registry only a minority of patients were at target goals for blood pressure, glucose, cholesterol, body weight, and nonuse of tobacco (Bhatt et al. 2006) . Notably, in all reported studies, treatment intensity was dependent on comorbidity: if in addition to PAD, coronary heart disease (CHD) or cerebrovascular disease (CVD) was concomitantly present, treatment rates had consistently improved.
It should be noted that current treatment recommendations for PAD patients are based on various strengths of evidence. The recommendation for smoking cessation (counseling, nicotine replacement, bupropion) is based on evidence level Ib (consistent evidence, based on a single randomized or on nonrandomized studies) and for physical exercise on Ia (several randomized studies or meta-analyses available). In contrast, the evidence is considered to be weaker for lipid-lowering (level IIb) and diabetes treatment (IIc). While the evidence for the use of antiplatelet drugs is strong (Ia), it should be noted that the underlying data are based on symptomatic patients. While antiplatelet therapy has been recommended in diabetic patients and/or PAD patients (American Diabetes Association 2003; American Diabetes Association 2007), the recent results of the POPADAD study in patients with diabetes and concomitant asymptomatic PAD did not provide evidence to support the use of acetylsalicylic acid (ASA) or antioxidants in the primary prevention of cardiovascular events and mortality (Belch et al. 2008) . Similarly, in the large Japanese JPAD study, primary prevention in diabetic patients with low-dose ASA therapy did not reduce vascular event rates (Ogawa et al. 2008) . Very recently, Fowkes et al. reported the results of the Aspirin for Asymptomatic Atherosclerosis (AAA) study: Among participants without clinical cardiovascular disease, identified with a low ABI based on screening a general population, the administration of ASA compared with placebo did not result in a significant reduction in vascular events (Fowkes et al. 2010) .
Other reasons beyond the varying strength of evidence may account for the reluctance of physicians to adhere to the PAD guidelines. Basically, many physicians still underestimate the importance of PAD in relation to CHD or CVD (Belch et al. 2003) . Secondly, the expectation in the management of younger patients that lifestyle change or other nonpharmacological treatment may be sufficient (Pickering 2003) , and in the elderly the fear of doing harm by applying overly intensive treatment for example with regards to antihypertensive therapy (Berlowitz et al. 1998; Chobanian 2001) , accounts for undertreatment. Further, the high number of guidelines in various fields, and their length and complexity, makes it difficult for the physician to keep abreast with the plethora of information. Clinical inertia on the side of physicians might be the result (Phillips et al. 2001) .
With respect to outcomes at 1.5 years, in our study the total incidence of deaths and vascular events was 23.5%, an unexpectedly high rate, which hints at the inclusion of patients with advanced disease (or multiple risk factors). For comparison, in PAD patients the 1-year incidences of death plus major vascular events were 8.3% in getABI (Lange et al. 2005 ) and 5.4% in REACH (Steg et al. 2007 ).
For our investigation, we chose a real-life, noninterventional study design in order to obtain data on actual practice patterns. This ensured that various types of PAD patients with a broad variety of concomitant diseases or medications could be investigated. However, when interpreting the results of the present study, several limitations have to be taken into account. Firstly, the study was observational and not randomized, which means that unknown biases cannot be ruled out (Benson and Hartz 2000; Sinatra et al. 2005) . While physicians were requested to document eligible patients consecutively, there was no additional log file of all patients in the practice to exclude possible selection processes. Further, no data are available about those patients who could not be followed up. The rate of patients lost to follow-up was substantial (about a quarter), and it can be hypothesized that these patients are less well treated than more compliant patients. No information was collected on reasons why guideline-oriented treatment was not pursued (example: contraindication to exercise training in patients with musculoskeletal disease or due to acute cold). The missing difference between outcomes in the guideline-oriented and nonguideline-oriented groups may be due to various factors, which comprise low treatment intensity and therefore unsatisfactory clinical effect and underestimation of the implications of PAD (Hirsch et al. 2007 ) with resulting patient noncompliance or nonadherence to therapy. Further, a lack of effect in certain subgroups, e.g., missing effect of antithrombotic therapy in the asymptomatic patients as noted in the AAA study (Fowkes et al. 2010) , or in the high Fontaine stages might account for the non-differentiation. Finally, methodological issues cannot be fully excluded, such as misclassification of events.
Conclusions
The present PAD cohort was a high-risk sample with an unexpectedly high rate of deaths and vascular events. The proportion of patients treated comprehensively according to the guidelines was relatively low, which calls for an optimization. There was a lack of differentiation between the guideline-oriented and non-guideline-oriented therapy in terms of outcomes, which may be due to patient-related or other factors, and calls for further research.
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